NCT04841538 2022-04-29
A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors
Elpiscience Biopharma, Ltd.
Phase 1/2 Withdrawn
Elpiscience Biopharma, Ltd.
Virginia Commonwealth University
University of Maryland, Baltimore
Masonic Cancer Center, University of Minnesota
Case Comprehensive Cancer Center